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Piccolo genotype modulates neural correlates of
emotion processing but not executive functioning
S Woudstra1,2,3,4,5, Z Bochdanovits2,5, M-J van Tol6,7, DJ Veltman1,5, FG Zitman3, MA van Buchem4,8, NJ van der Wee3,4,
EM Opmeer6, LR Demenescu6,9, A Aleman6,10, BW Penninx1,3,5,6 and WJ Hoogendijk1,5,11
Major depressive disorder (MDD) is characterized by affective symptoms and cognitive impairments, which have been
associated with changes in limbic and prefrontal activity as well as with monoaminergic neurotransmission. A genome-wide
association study implicated the polymorphism rs2522833 in the piccolo (PCLO) gene—involved in monoaminergic
neurotransmission—as a risk factor for MDD. However, the role of the PCLO risk allele in emotion processing and executive
function or its effect on their neural substrate has never been studied. We used functional magnetic resonance imaging (fMRI) to
investigate PCLO risk allele carriers vs noncarriers during an emotional face processing task and a visuospatial planning task in
159 current MDD patients and healthy controls. In PCLO risk allele carriers, we found increased activity in the left amygdala
during processing of angry and sad faces compared with noncarriers, independent of psychopathological status. During
processing of fearful faces, the PCLO risk allele was associated with increased amygdala activation in MDD patients only. During
the visuospatial planning task, we found no genotype effect on performance or on BOLD signal in our predefined areas as a
function of increasing task load. The PCLO risk allele was found to be specifically associated with altered emotion processing,
but not with executive dysfunction. Moreover, the PCLO risk allele appears to modulate amygdala function during fearful facial
processing in MDD and may constitute a possible link between genotype and susceptibility for depression via altered processing
of fearful stimuli. The current results may therefore aid in better understanding underlying neurobiological mechanisms in MDD.
Translational Psychiatry (2012) 2, e99; doi:10.1038/tp.2012.29; published online 3 April 2012
Introduction
Major depressive disorder (MDD) is a common, multifactorial
disorder and is one of the leading causes of years lost due to
disability.1,2 Its core symptoms are affective, manifesting
themselves in depressed mood accompanied by low
self-esteem and loss of interest in normally enjoyable
activities. Other MDD symptoms include cognitive impair-
ments, such as concentration and planning problems.3 The
presence and severity of both affective and cognitive
symptoms can be evaluated by neuropsychological assess-
ments,4 and may be reflected in altered regional brain activity
as measured using fMRI.5–7
Twin studies have shown that up to 40% of MDD is
genetically determined.8 Much of the candidate gene litera-
ture has focused on genes from the monoaminergic neuro-
transmitter system, such as the serotonin transporter,
monoamine oxidase A and tryptophan hydroxylase 2.9–14
A recent study by our consortium demonstrated that
candidate genetic association studies are not well repli-
cated,15 which suggests that a hypothesis-free approach
is more useful to identify possible genetic variants that
contribute to MDD. Previously, we conducted a genome-wide
association study (GWAS) in MDD using B500000 single-
nucleotide polymorphisms (SNPs), showing one SNP
(rs2522833) located at position 82453708 (hapmap genome
build 37.1) in the piccolo gene (PCLO) in particular to be of
interest in the genetic model for MDD.16 This association was
replicated in some studies,16–18 but not in others.19,20 The
rs2522833 SNP changes the hydrophilic, uncharged amino
acid serine to the charged amino acid alanine in the calcium-
binding C2A domain of PCLO and may affect protein
stability.21 The PCLO protein is localized at the cytomatrix of
the presynaptic active zone and is important in monoaminer-
gic neurotransmission in the brain.16,22 Recently, Schuhma-
cher et al.23 showed that the PCLO SNP rs2522833 is
associated with antidepressant treatment response, support-
ing the involvement of PCLO in MDD. The mechanism
through which this PCLO risk allele contributes to MDD is
not known, but its primary role in monoaminergic neurotrans-
mission suggests that it may affect activity of brain circuitry
involved in emotional information processing and/or executive
functioning in MDD.24
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Abnormal emotion processing of, for example, facial stimuli
is one of the intermediate phenotypes that can be considered
closer to the neurobiological substrate of MDD than the
clinical diagnosis itself.6 Identification of emotional facial
expressions is reportedly impaired in MDD,25 and functional
imaging studies have shown aberrant activity of emotional
face processing related areas, including the amygdala,
striatum, insula, parahippocampal area and dorsolateral
prefrontal cortex (PFC), using an emotional faces task in
healthy controls (HC).26 It is thought that serotonin has an
important role in emotional face processing and dysregulation
of the serotonergic system is associated with altered
amygdala activity as well as the occurrence of MDD.9,27,28
Another intermediate phenotype for MDDmay be executive
dysfunction, including impaired working memory and plan-
ning/problem solving. Previous studies in MDD have shown
abnormal task performance and increased activity in task-
related brain areas,7,29,30 using the Tower of London visuo-
spatial planning task (ToL) and the n-back working memory
task.31–34 Apart from the PFC, other areas involved in
planning include the striatum, and a visuospatial processing
system, including the precuneus and inferior parietal cor-
tex.29,34 The association of executive function with mono-
aminergic neurotransmission is thought to be bidirectional:
PFC function is shaped by monoaminergic neurotransmitters,
but ascending modulatory monoaminergic systems may also
be affected by the PFC.24 Studies suggests that the PFC is
able to recruit monoamine systems in specific circumstances,
for example, to optimize the coping strategy for stress.35,36
Over the last few years, imaging genetics has shown to be a
powerful tool in unraveling neurobiological pathways in
various psychiatric disorders. However, to date, studies in
MDD have been rare,10,37,38 and the role of the PCLO risk allele
on emotional information processing and executive function
has never been studied. Given that PCLO is associated with
MDD, we hypothesized that the PCLO risk allele—relative to
the nonrisk allele—is associated with similar changes in
activity in emotional processing and in executive function
related areas as described for MDD. In addition, we aimed to
investigate the relationship of PCLO with current psycho-
pathology during emotional face processing and executive
function.
Materials and methods
Subjects. A sample of 159 subjects participating in the
Netherlands Study for Depression and Anxiety (NESDA) was
selected to take part in this genetic neuroimaging study.
Details of the NESDA study are extensively described else-
where.39 Genotype data were collected through the genetic
association information network (GAIN) study for MDD, in
which 1862 cases and 1857 controls were genotyped.40
Magnetic Resonance Imaging (MRI) data were available
from the MRI NESDA study, in which 301 subjects aged
between 18 and 57 years participated.41 During a 1-h protocol,
subjects underwent MR imaging while performing different tasks,
including the ToL paradigm, the emotional faces paradigm and
a verbal memory task, structural imaging and resting state
imaging.
Exclusion criteria were: presence of MRI contraindications,
DSM-IV axis I disorder other than MDD, Panic Disorder or
social anxiety disorder (except generalized anxiety disorder)
lifetime, or any DSM-IV disorder (for HC), dependence or
recent abuse of alcohol and/or drugs, hypertension, major
internal and/or neurological disorders and use of psychotropic
medication (other than stable use of a selective serotonin
reuptake inhibitor (SSRI) or incidental use of benzodiaze-
pines). To assess depressive symptom characteristics and
severity scores, the Inventory of Depressive Symptomatol-
ogy42 and the Montgomery–A˚sberg Depression Rating
Scale,43 were used. For the present report, we included only
subjects that met the 6-month recent DSM-IV criteria for
current MDD, or no lifetime DSM-IV diagnosis. Owing to
missing genotype data, technical problems during scanning
and/or insufficient task performance, our final sample for
this study consisted of 126 subjects for the emotional face
processing study and 159 subjects for the executive
function study (see Supplementary Table 1 for an over-
view). All participants provided written informed consent
and the study was approved by the Ethics Committees at
the VU University Medical Center, Amsterdam, the Leiden
University Medical Center and the University Medical
Center Groningen.
Demographics. The 126 subjects in the emotional faces
study included 91 PCLO risk allele carriers (PCLOþ ; 25
homozygous and 66 heterozygous for the ‘C’ risk allele) and
35 homozygous ‘A’ nonrisk allele carriers (PCLO). The ratio
of PCLOþ and PCLO in the executive function study did
not significantly differ (110 PCLOþ ; 33 homozygous and 77
heterozygous for the ‘C’ risk allele, and 49 homozygous ‘A’
nonrisk allele carriers; PCLO) from the ratio in the
emotional faces study (w2 [df 1]¼ 0.31; P40.05). For the
analyses, we formed two groups: one group consisting of
subjects carrying the risk allele, and one group consisting of
subjects not carrying the risk allele. From this point forward,
we will refer to these groups as PCLOþ and PCLO,
respectively. PCLO groups did not differ with regard to age,
gender, education, MDD/HC ratio, depression severity or
SSRI use/duration (see Table 1). Thirty-four individuals were
using SSRIs, and 15 individuals were using nonpsychotropic
medication other than SSRIs. All subjects reported Western
European ancestry.
Genotyping. Genotyping for the genetic association
information network study was performed by Perlegen and
is described in detail elsewhere.16 Observed genotypes in our
sample did not deviate from Hardy–Weinberg equilibrium
(emotional face processing paradigm): w2 [df 2]¼ 0.37;
P40.05; CC: AC: AA¼ 35:66:25; P40.05; executive fun-
ctioning paradigm: w2 [df 2]¼ 0.07; CC: AC: AA¼ 33:77:49;
P40.05; http://www.oege.org/software/hardy-weinberg.html).
Emotional information processing paradigm. An emotional
faces task, based on the event-related fMRI paradigm used
by Wolfensberger et al.44 was used in the present study and
has been extensively described elsewhere.5 Briefly, 24
stimuli—selected from the Karolinska Directed Emotional
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Faces System45—were chosen for each of five facial
expressions (angry, fearful, sad, happy and neutral), compris-
ing 12 female and 12 male faces.
Each particular face was not presented more than four
times. The control condition (scrambled faces) was presented
80 times. While functional MRI data were collected, subjects
were asked to indicate each face’s gender using a button box.
During the presentation of scrambled faces, participants had
to press left or right buttons in conformity with the instruction
presented on the screen, that is, an arrow pointing to the left or
to the right. The reaction time (RT) was recorded and used as
performance measure.
Executive function paradigm. An event-related parametric
version of the ToL task was used to investigate the neural
correlates of planning, an aspect of executive functioning.7,34
Briefly, while functional MRI data were collected, subjects
were asked to work out the minimum number of steps
needed—ranging from one to five moves—to get from the
start position to the goal position, which were both presented
on a screen simultaneously. In the baseline condition,
subjects were asked to count the number of yellow and
blue beads. RT and proportion of correct answers were used
as performance measures.
MRI data acquisition. The functional neuroimaging
methods have been comprehensively reported elsewhere.5,7
In summary, T2*-weighted echo-planar images sensitive to
the blood oxygenation level–dependent (BOLD) effect were
acquired using similar Philips 3T MR systems (repetition time
(TR)¼ 2300ms, echo time (TE)¼ 30.0ms (UMCG: 28.0ms),
situated at different locations (Amsterdam, Leiden, and
Groningen, the Netherlands). The echo-planar images’
volumes were acquired at 35 slices (UMCG: 39 slices),
interleaved acquisition, 3mm thickness. The matrix sizes
were 96 96 voxels (UMCG: 64 64 voxels). The in-plane
resolution was 2.29 2.29mm2 (UMCG: 3 3mm2). The
images were acquired parallel to the anterior-posterior
commissure plane. A T1-weighted anatomical MRI was also
acquired for each subject (TR¼ 9ms, TE¼ 3.5ms, matrix
size 256 256, voxel size 1 1 1mm3).
Analysis
Performance. Faces paradigm: RT were analyzed with
SPSS (SPSS, Chicago, IL, USA) by means of a repeated-
measures analysis of covariance (ANCOVA), using RT per
valence as dependent factor, group (PCLOþ , PCLO) as
between subject factor and age, scan location, and years of
education as covariates. Significance for behavioral analyses
was set at 5%, and post hoc paired tests were Bonferroni-
corrected for multiple comparisons. Post hoc analyses were
performed to test for interaction using a univariate general
linear model.
ToL paradigm: performance data (accuracy and RT) were
analyzed with SPSS (SPSS). Performance was analyzed by
means of a repeated-measures ANCOVA, using the propor-
tion correct scores and mean response times per trial type as
dependent factors, group (PCLOþ , PCLO) as between
subject factor, and age as a covariate. Significance for
behavioral analyses was set at 5%, and post hoc paired tests
were Bonferroni-corrected for multiple comparisons.
Imaging data analysis. Image processing was performed
using Statistical Parametric Mapping (SPM; SPM5—http://
www.fil.ion.ucl.ac.uk/spm/) software implemented in Matlab
7.5.0 (The Matlab, Natick, MA, USA). Details of
preprocessing and first level single-subject analyses have
been described elsewhere.5,7 Briefly, following temporal and
spatial preprocessing stimulus responses were modeled
using delta functions convolved with a synthetic
hemodynamic response function. For both paradigms, trial
duration was also modeled.46 In the faces task, four contrast
images were generated for each subject: ‘angry4neutral’,
‘fearful4neutral’, ‘sad4neutral’ and ‘happy4neutral’. These
contrasts ensured that visual input only differed in its
emotional content and were entered in a second-level
mixed effect analysis. For the ToL task, activation maps
associated with increased task load were calculated per
subject, and contrast images were likewise included in a
second-level mixed-effect analysis.
Statistical association analysis. The amygdala and ventral
striatum were determined a priori as regions of interest (ROI)
for the emotional faces task. Positive effects of task across
Table 1 Demographic characteristics of total sample
Characteristics Tower of London planning task Emotional face paradigm
Genotype Genotype
Total PCLO+ PCLO v2 P-value Total PCLO+ PCLO v2 P-value
Number of subjects 159 110 49 126 90 36
Gender (%female) 64.1 64.5 63.3 0.024 40.05 61.9 61.1 63.8 0.08 40.05
Age (mean years±s.d.) 38.17 (10.7) 37.9 (10.2) 38.8 (11.9) 40.05 38.1 (10.3) 38.0 (10.2) 38.4 (10.7) 40.05
Education (mean years±s.d.) 12.5 (3.1) 12.8 (3.3) 11.9 (2.8) 40.05 12.6 (3.1) 12.8 (3.2) 12.1 (2.8) 40.05
Scan center (A/L/G) 42/62/55 28/46/36 14/16/19 1.21 40.05 24/54/48 19/40/31 5/14/17 1.99 40.05
Diagnosis (MDD/HC) 118/41 84/26 35/15 0.86 40.05 96/30 69/21 27/9 0.04 40.05
IDS (mean score±s.d.) 18.90 (13.5) 20.06 (13.2) 16.27 (14.0) 40.05 19.46 (13.9) 20.05 (13.6) 17.91 (14.8) 40.05
MADRS (mean score±s.d.) 11.89 (10.4) 13.01 (10.3) 9.39 (10.1) ¼ 0.042 12.78 (10.4) 13.53 (10.3) 10.80 (10.4) 40.05
Duration of SSRI use
(months±s.d.)
22.91 (37.6) 27.77 (38.8) 18.80 (36.5) 40.05 23 (36.9) 24.75 (37.7) 18.8 (36.5) 40.05
SSRI use (no/yes) 119/40 82/28 37/12 40.05 92/34 67/24 25/10 40.05
Abbreviations: HC, healthy controls; IDS, inventory of depressive symptomatology; MADRS, Montgomery–A˚sberg Depression Rating Scale; MDD, major depressive
disorder; PCLO, piccolo; SSRI, selective serotonin reuptake inhibitor.
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whole brain are reported at a threshold of Po0.05 familywise
error corrected for multiple comparisons (PFWEo0.05). We
conducted an ANCOVA for the faces task with genotype as an
independent factor, to test whether the PCLO risk allele is
associated with altered activity in the amygdala during
processing of negative faces. Age and scan location were
used as covariates. A threshold of Po0.05 FWE corrected
using the small volume correction (PFWE_SVCo0.05) procedure
implemented in SPM5 for the amygdala was considered
significant. For this small volume correction, we used the
automated anatomical labeling atlas,47 implemented in the
Wake Forest University Pick Atlas toolbox. To test whether the
PCLO risk allele is associated with altered increased activity in
the amygdala and ventral striatum during processing of
positive faces, we conducted an ANCOVA with genotype as
an independent factor. Age and scan location were used as
covariates. A threshold of PFWE_SVCo0.05 (using the
automated anatomical labeling atlas, implemented in the
Wake Forest University Pick Atlas toolbox) for amygdala and
ventral striatum was considered significant.
For the executive function task, regions activated with
increasing task load were determined a priori as ROIs
according to the areas described in van den Heuvel et al.34
(including dorsolateral PFC). Main effects of increasing task
load are reported at a threshold of Po0.05 whole-brain FWE
corrected for multiple comparisons. Next, an ANCOVA using
genotype as independent factor was conducted, to test
whether the PCLO risk allele is associated with altered brain
activity associated with increasing task load. Age, gender,
education and scan location were used as covariates. Owing
to dorsolateral PFC size, a threshold of PFWE_SVCo0.05
(10mm radius around the peak voxel that was found in the
main effect of condition) was considered significant.
We conducted post hoc analyses for both tasks to test
whether interaction of genotype with current psychopathology
occurred. A threshold of PFWE_SVCo0.05 (6mm radius
sphere for amygdala and striatum and 10mm radius sphere
for cortical areas around the peak voxel) in the ROIs was
considered significant.
Results
Processing emotional faces
PCLO genotype effect on task performance. We did not find
significant genotype or genotype x valence effects on task
performance (RT) during emotional face processing.
Additional genotype x diagnosis x valence effects on RT
revealed interaction effects between PCLO genotype and MDD
diagnosis for angry, fear and sad faces (RT_angry: PCLO*MDD;
P¼ 0.0595; RT_fear: PCLO*MDD; P¼ 0.0493; RT_sad:
PCLO*MDD; P¼ 0.0395; see Supplementary Table 3).
BOLD fMRI results
Main effect of task during processing of faces. Processing
angry faces compared with neutral faces was associated with
robustly increased activity of bilateral amygdala as well as
bilateral putamen, ventrolateral PFC, superior and middle
temporal lobe and inferior parietal cortex. Processing
fearful faces compared with neutral faces was similarly
associated with increased activity of bilateral amygdala as
well as of bilateral parietal cortex, right temporal cortex,
bilateral occipital cortex, bilateral amygdala, decreased
activity of ventral striatum and right parahippocampal
gyrus. Processing sad faces compared with neutral faces
activated bilateral amygdala, striatum, insula, parahippo-
campal area and dorsolateral PFC.
For happy faces, we observed activation in bilateral
amygdala and ventral striatum as well as in bilateral occipital
cortex, inferior parietal cortex and posterior cingulate cortex.
PCLO genotype effect during processing of faces. We found
significantly increased activity in the left amygdala in the
PCLOþ group, relative to the PCLO group, during process-
ing of negative faces (angry vs neutral: (MNI coordinates
x¼21 y¼ 0 z¼15, Z¼ 3.6, PFWE_SVC¼ 0.004, (Figure 1);
fear vs neutral: MNI coordinates x¼18 y¼ 0 z¼18,
Z¼ 3.24, PFWE_SVC¼ 0.014, (Figure 2); and trendwise for sad
vs neutral: MNI coordinates x¼15 y¼3 z¼18, Z¼ 2.6,
PFWE_SVC¼ 0.067).
We did not observe significant effects of PCLOþ within our
ROIs during processing of happy faces. However, we found
subtreshold increased activity in the left amygdala during
processing of happy faces compared with neutral faces (MNI
coordinates x¼24 y¼ 3 z¼15; Z¼ 2.47; PFWE_SVC
o0.09, Puncorrected¼ 0.007). In addition, during processing
of happy faces we found a near-significantly decreased
activity for the PCLOþ group in the right ventral striatum
(MNI coordinates x¼ 9 y¼ 6 z¼9; Z¼ 2.67; PFWE_SVCE
0.05 (P¼ 0.058) Puncorrected¼ 0.004).
We found similar results as reported for negative vs neutral
faces, and plotting our data suggested that these effects were
indeed driven by negative faces.
Interaction of PCLO genotype with current psychopathology
during processing of faces. Post hoc analyses showed a
Figure 1 Effect of piccolo (PCLO) genotype on emotion processing of angry vs
neutral faces (MNI coordinates (x¼21 y¼ 0 z¼15), Z¼ 3.6, PFWE¼ 0.004).
Activation shown at Po0.005, uncorrected.
Piccolo genotype and emotion processing
S Woudstra et al
4
Translational Psychiatry
significant genotype by depression interaction (F(1,119)¼
9.50; Z¼ 2.8) during processing of fearful faces compared
with neutral faces: PCLOþ demonstrated increased amyg-
dala activity in the MDD group (Z¼ 3.02; pFWE o0.05), but
not in HC (Z¼ 1.1; Figure 3). There was no interaction during
processing of sad or angry faces or during processing of
happy faces. Notably, we found no main effect of diagnosis
on amygdala activation, which is similar to our previous
study.5
Executive functioning
PCLO genotype effect on task performance. No effect of
genotype was observed on task performance (mean RT:
PCLOþ : 8.30 s±2.34; PCLO: 8.19 s±2.11; P¼ 0.76;
repeated measures ANOVA for RT per trial type:
P¼ 0.094; proportion of correct answers: PCLOþ : 0.92±
0.08; PCLO: 0.90±0.11; P¼ 0.22; repeated measures
ANOVA for proportion of correct answer per trial type:
P¼ 0.488).
BOLD fMRI results
Main effect of task during executive functioning. In
accordance with previous studies,7,34 increasing task load
during the ToL was associated with robust activity in the
right dorsolateral PFC, right middle PFC, bilateral precuneus
and bilateral inferior parietal lobe (Figure 4; Supplementary
Table S2).
PCLO genotype effect during executive functioning. We
found no significant effect of genotype in the predefined
ROIs.
Interaction of PCLO genotype with current psychopathology
during executive functioning. Explorative post hoc analyses
showed a genotype by diagnosis interaction effect in the
left medial dorsolateral PFC (Brodmann’s area 9, MNI
coordinates x¼27 y¼ 30 z¼ 24, Z¼ 3.77, PFWEo0.05).
Increased activity in PCLOþ group compared with PCLO
was found in the MDD group but not in HC.
Confounding factors. As is known from other studies,
SSRI use may alter regional brain function in psychiatric
diseases.48 We conducted post hoc analyses for both the
emotional face paradigm and the planning paradigm to test
for possible effects of SSRI use. During processing of the
various emotional faces (angry vs neutral, fear vs neutral,
sad vs neutral and happy vs neutral), we found similar results
after excluding subjects using SSRIs from the main analyses.
Notably, we replicated the effect of PCLOþ for the left
amygdala.
Figure 3 Parameter estimates and 95% confidence intervals showing direction
of interaction effect of genotype and current psychopathology during processing of
fearful faces.
Figure 4 Positive effect of increasing task load on activation during planning.
Areas involved in the effect of increasing task load include the dorsolateral prefrontal
cortex (PFC), middle PFC, precuneus and inferior parietal lobe. Familywise error
corrected at Po0.05. Colors indicate Z-scores.
Figure 2 Effect of piccolo (PCLO) genotype on emotion processing of fearful vs
neutral faces (MNI coordinates (x¼18 y¼ 0 z¼18), Z¼ 3.246,
PFWE¼ 0.014). Activation shown at Po0.005, uncorrected.
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Also, post hoc analyses of imaging data of our executive
functioning paradigm revealed similar results after excluding
subjects using SSRIs as in the main analyses (data not
shown).
Discussion
We report, for the first time and in a large group of subjects, an
effect of the PCLO risk allele for MDD on amygdala activity
during processing of angry, fearful and (trend wise for) sad
facial expression, but not during happy facial processing.
During angry and sad facial processing, PCLO risk allele
carriers demonstrated increased amygdala activation, inde-
pendent of psychopathological status. During the processing
of fearful faces, only MDD patients with the PCLO risk allele
showed increased amygdala activation, whereas no effect of
genotype was observed in HC. At a behavioral level, MDD
patients with the PCLO risk allele performed near-significantly
faster than MDD patients with the nonrisk allele, whereas in
HC, no significant differences between PCLO genotype were
observed during perception of negative emotions. We found
no main effect of genotype on executive function, or on its
neural substrate, although explorative analyses indicated
MDD-specific effects of PCLO risk allele carriers in the medial
prefrontal area.
Dysregulation of the amygdala during emotional informa-
tion processing has previously been associated with
MDD.49–52 However, imaging findings have been inconsis-
tent, as several studies failed to demonstrate altered
amygdala activity during emotional information processing
of faces.5,53–57 We suggest that genetic heterogeneity may
explain, at least in part, the inconsistencies seen in the
literature. Increased amygdala responsiveness during nega-
tive face processing and decreased ventral striatum activity in
response to positive stimuli have also been reported in MDD
studies. Our findings provide further evidence for PCLO being
involved in the pathogenetic mechanisms underlying MDD.
We found a significant interaction between genotype and
current psychopathology, demonstrating increased activity in
the amygdala in MDD patients relative to HC during
processing of fearful faces. Involvement of the amygdala in
the neural response to fearful faces, but not to angry or sad
faces has been suggested by some studies,58–60 but not by
others.61,62
Our study showed lateralization effects in the amygdala in
the PCLO risk allele group, which may reflect a bias towards a
more specific, sustained emotional reaction in the left
amygdala, rather than the general emotional reaction in
which the right amygdala is reportedly involved.63 It has also
been proposed that lateralization may be associated with the
temporal dynamics of the amygdala in response to emotional
stimuli. Whereas the left amygdala is presumably involved
in stimulus evaluation, the right amygdala has been implicated
in the rapid detection of emotional stimuli.64 Following this
line of argument, we suggest that the PCLO variant may
modulate evaluation of emotional faces, rather than their rapid
detection.
In MDD, treatment with SSRIs may reduce negative bias in
perception and memory.65–67 In addition, it is thought that
changes in serotonergic neurotransmission can modulate
identification of emotional faces, particularly fearful faces.65,66
Recently, the PCLO risk allele was found to enhance the
biological response to SSRIs among MDD patients.23 How-
ever, the mechanism of PCLO modulation on serotonin
transmission is unclear and may not involve the serotonin
transporter, also in view of the inconsistent findings asso-
ciated with other serotonergic polymorphisms.68,69
We found no effect of the PCLO risk allele on performance
or BOLD signal during an executive paradigm, the ToL
planning task. However, post hoc, we found an interaction
between genotype and current psychopathology during
performance of the ToL in the left middle dorsolateral PFC,
which was also found to be associated with depression
severity.7 However, these results should be interpreted with
care, as these findings were based on explorative analyses.
Another potential limitation of our study is that our results
cannot be readily generalized outside the field of planning and
problem solving, and emotional faces processing field.
Taken together, our findings during emotional face proces-
sing and planning indicate that PCLO is associated with
emotion processing rather than executive function. Although
our findings suggested selectivity of PCLO for serotonergic
neurotransmission relative to other monoamines, such a
hypothesis is in need of empirical testing. Therefore, future
fMRI studies should seek to employ combined cognitive-
emotional paradigms coupled with pharmacological manip-
ulation to further investigate the role ofPCLO in emotional and
cognitive processing.
In conclusion, the PCLO risk allele is associated with
increased activity in the left amygdala during emotional
information processing of negative faces, but not with
executive function or its neural substrate. We suggest that
our data support the role of thePCLO risk allele as a risk factor
for MDD through altered amygdala activity and, possibly,
altered serotonergic neurotransmission in brain areas related
to emotional information processing.
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